Document is current
Any future updates will be listed below
-
Authors
Hu, Zhen
Yu, Qianqian
Chen, Liqin
Su, Tingting
Berrocal-Almanza, Luis C.
Miranda, Miguel
Xu, Xiaoqing
Ru, Meng
Zhao, Tianyu
Miao, Feng
Xie, Mengyu
Shao, Zhimin
-
Funding
Funding for this research was provided by:
AstraZeneca
Merck Sharp & Dohme LLC
- License Information
-
More Information
Article History
Received: 13 June 2025
Accepted: 22 September 2025
First Online: 26 October 2025
Declarations
:
: Luis C. Berrocal-Almanza, Meng Ru and Xiaoqing Xu are employees and stockholders of AstraZeneca. Miguel Miranda was an employee of AstraZeneca at the time of the study and holds stock with AstraZeneca. Their current affiliation is with Amgen. Tianyu Zhao was an employee of Hangzhou Tigermed Consulting Co., Ltd., which provides consulting services to AstraZeneca, at the time of this study, and declares no current affiliation. Feng Miao and Mengyu Xie are employees of Hangzhou Tigermed Consulting Co., Ltd., which provides consulting services to AstraZeneca. Liqin Chen, Zhen Hu, Zhimin Shao, Tingting Su and Qianqian Yu declare that they have no competing interests.
: As this was a retrospective, observational study and all data were deidentified, an informed consent waiver was approved by the FUSCC Ethics Committee (approval #2207256-7). This observational study was approved by the Human Genetic Resource Administration of China.
